Sanofi-backed Electra Therapeutics files for Nasdaq IPO to fund Phase 2/3 immunology program
read at Endpoints ↗DealPositive
Electra Therapeutics announced it has filed with securities regulators to begin trading on the Nasdaq shortly after the Labor Day holiday.
The Sanofi-backed biotech aims to raise capital through the offering to support the continued development of its Phase 2/3 immunology drug candidate.
The filing underscores that biotech IPO activity remains active this summer, with Electra planning to launch its public debut in the coming weeks.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drug”
read at Endpoints ↗84 words · retrieved 3h ago
comments(0)
5-min edit window · permanent after that